nach oben

Erschienen in:

01.12.2023 | News item

InvaGen recalls one lot of Vigabatrin for Oral Solution

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

The US FDA has published a company announcement from Cipla advising that its subsidiary InvaGen Pharmaceuticals is voluntarily recalling one lot of Vigabatrin for Oral Solution, USP 500mg, due to a seal integrity issue allowing powder leakage from the sachet. …

InvaGen Pharmaceuticals Issues Voluntary Nationwide Recall of Vigabatrin for Oral Solution, USP 500mg due to Leaking Sachets Internet Document : 11 Dec 2023. Available from: URL: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/invagen-pharmaceuticals-issues-voluntary-nationwide-recall-vigabatrin-oral-solution-usp-500mg-due

Titel: InvaGen recalls one lot of Vigabatrin for Oral Solution
Publikationsdatum: 01.12.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-51981-2

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

InvaGen recalls one lot of Vigabatrin for Oral Solution

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Levocarnitine/Valproic-acid

Tranexamic-acid

Risperidone/sertraline/topiramate

Bendroflumethiazide/Furosemide/Spironolactone

Amitriptyline/escitalopram/nortriptyline

Biosimilars and reference biologics: no issues when switching